New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:36 EDTFLMLFlamel announces positive results of FIM clinical trial with Micropump
Flamel Technologies announced that its First-in-Man, or FIM, clinical study in healthy volunteers using its proprietary Micropump technology applied to sodium oxybate has identified formulations that demonstrate the potential to eliminate the second nighttime dose for patients suffering from narcolepsy achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, eliminating the need for a second dose. The current dosing regimen for the standard of care, Xyrem, in the United States is two equal, divided doses: the first dose at bedtime and the second dose 2.5 to 4 hours later. The elimination of the second dose for narcolepsy patients would not only provide more convenience, but may improve the benefit sodium oxybate provides as there will be no disruption to nighttime sleep. The potential for additional benefits, including improved safety, will be studied.
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:47 EDTFLMLFlamel Technologies pullback a buying opportunity, says Summer Street
Subscribe for More Information
08:33 EDTFLMLFlamel Technologies transfers intangible property to Irish-based subsidiary
Flamel Technologies announced that it is moving all intangible property from its French entity to its Irish-based entity as a part of a global reorganization. The intangible property includes patents on its drug delivery platform technologies, clinical data sets and other intangible assets related to its pipeline of proprietary products in development. Flamel's proprietary drug delivery platforms include its Micropump and Medusa platforms. The company anticipates the transfer will result in a one-time tax payment of approximately $14M to the French government. The transfer of these assets is effectively immediately.
December 10, 2014
10:27 EDTFLMLFlamel Technologies management to meet with Roth Capital
Subscribe for More Information
December 8, 2014
07:45 EDTFLMLFlamel Technologies price target raised to $29 from $21 at SunTrust
SunTrust increased its price target on Flamel after meeting with the company's CEO, as the firm now expects the company to raise the price of its Bloxiverz drug next year beyond the firm's previous outlook. SunTrust keeps a Buy rating on the shares.
December 3, 2014
09:26 EDTFLMLFlamel Technologies added to Focus List at Roth Capital
Roth Capital added Flamel to its Focus List, as the firm expects the company's revenue and EPS to jump next year, largely due to a ramp in sales of its Bloxiverz drug. The firm reiterates a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use